{"entity":{"id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","aka":[],"tldr":"Farletuzumab-exatecan is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials, aimed at Folate receptor alpha.","summary":"Farletuzumab-exatecan (SYS6041) is an antibody-drug conjugate developed by CSPC Megalith Biopharmaceutical. Its target is Folate receptor alpha (the sponsor names Folate receptor alpha (FRα)). The sponsor states: SYS6041 (farletuzumab-exatecan) is an antibody-drug conjugate targeting human folate receptor alpha with a topoisomerase I inhibitor payload, given by intravenous injection on day 1 of each three-week cycle. ClinicalTrials.gov describes the intervention as: Farletuzumab-exatecan antibody-drug conjugate targeting human FRα. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07744763, plans to enrol 260 participants with primary completion expected 2027-03-28. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Farletuzumab-exatecan","url":"https://clinicaltrials.gov/search?intr=Farletuzumab-exatecan"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["folr1"],"drugs":[],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07714668","nct07744763"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"SYS6041","modality":"ADC","mechanism":"SYS6041 (farletuzumab-exatecan) is an antibody-drug conjugate targeting human folate receptor alpha with a topoisomerase I inhibitor payload, given by intravenous injection on day 1 of each three-week cycle.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/farletuzumab-exatecan/","neighbours":{"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}],"trial":[{"id":"nct07714668","kind":"trial","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","route":"/trials/nct07714668/"},{"id":"nct07744763","kind":"trial","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","route":"/trials/nct07744763/"}]}}